首页> 外文期刊>Cardiovascular therapeutics >Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry
【24h】

Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry

机译:Takotsubo心肌病伴左心室流出道梗阻期间静脉输注艾司洛尔的血流动力学影响,安全性和可行性:多中心注册中心的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Betablockers are considered the most suitable treatment for such complication. Aim of the study: The objective of this study was to evaluate the hemodynamic effects, safety, and feasibility of a selective beta-blocker (beta 1) with a short half-life, esmolol, in subjects with a TTC episode. Methods: Ninety-six consecutive patients with TTC were enrolled in a multicenter registry. The hemodynamic and echocardiographic effects of esmolol (0.15-0.3 mg/kg/min) were analyzed in nine consecutive patients with LVOTO. Clinical course of patients, hemodynamics, days of hospitalization, LV function, and adverse events at follow-up were recorded. Results: Left ventricular outflow tract obstruction was present in 10 (10.4%) of 96 patients. Patients with LVOTO were older and had higher values of troponin-I at admission. LV ejection fraction at admission (36.1 +/- 8.4%) significantly improved at discharge (51.4 +/- 6.9%, P = 0.001). Among patients treated with esmolol infusion, LVOT pressure gradient before treatment was 47.6 +/- 16.6 mmHg and after 18.2 +/- 2.3 mmHg (P = 0.0091). Systolic blood pressure decreased from 123.8 +/- 29.1 to 112.6 +/- 12.7 mmHg (P = 0.1537). Mean hospital stay was 9 +/- 2 days. No adverse events were observed during hospitalization and at follow-up. Conclusions: Esmolol infusion was temporally associated with reduction in intraventricular gradient and systemic blood pressure in patients with TTC and LVOTO. Further controlled studies are warranted to confirm these preliminary findings.
机译:背景:左室流出道梗阻(LVOTO)可能使Takotsubo心肌病(TTC)发作复杂化,可能导致心源性休克。 Betablockers被认为是最适合此类并发症的治疗方法。研究的目的:这项研究的目的是评估具有半衰期短的艾司洛尔的选择性β-受体阻滞剂(β1)在TTC发作中的血液动力学效应,安全性和可行性。方法:将96例连续的TTC患者纳入多中心注册中心。在连续9例LVOTO患者中分析了艾司洛尔(0.15-0.3 mg / kg / min)的血流动力学和超声心动图影响。记录患者的临床病程,血液动力学,住院天数,左室功能和随访中的不良事件。结果:96例患者中有10例(10.4%)存在左室流出道梗阻。 LVOTO患者年龄较大,入院时肌钙蛋白I值较高。入院时左室射血分数(36.1 +/- 8.4%)在出院时明显改善(51.4 +/- 6.9%,P = 0.001)。在接受艾司洛尔输注治疗的患者中,治疗前和治疗后LVOT压力梯度分别为47.6 +/- 16.6 mmHg和18.2 +/- 2.3 mmHg(P = 0.0091)。收缩压从123.8 +/- 29.1毫米汞柱降至112.6 +/- 12.7毫米汞柱(P = 0.1537)。平均住院时间为9 +/- 2天。住院期间和随访期间未观察到不良事件。结论:艾司洛尔的输注在时间上与TTC和LVOTO患者的脑室内梯度下降和全身血压降低有关。有必要进行进一步的对照研究以证实这些初步发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号